Sasineprocel’s future lies as a monotherapy in Parkinson’s disease, says GlobalData
Sasineprocel's encouraging Phase I/IIa data positions autologous iPSC-derived dopaminergic neuron therapy as a potential monotherapy challenger in Parkinson's di...



























